WY-14643 (Pirinixic Acid): Selective PPARα Agonist for Metabolic and Inflammation Research

Executive Summary: WY-14643 (Pirinixic Acid) is a highly selective agonist of peroxisome proliferator-activated receptor alpha (PPARα) with an IC₅₀ of 10.11 μM for human PPARα, providing a validated tool for metabolic disorder research (APExBIO). It exhibits dual modulation of both PPARα and PPARγ with enhanced activity via α-substitution, enabling fine-tuning of metabolic pathways (Sulfonhsssbiotin.com). WY-14643 has demonstrated the ability to downregulate TNF-α-induced VCAM-1 in endothelial cells, reducing monocyte adhesion and supporting anti-inflammatory applications (PubMed). In rodent models, oral administration at 3 mg/kg/day for two weeks lowers plasma glucose, triglycerides, and leptin, and enhances insulin sensitivity without promoting weight gain (APExBIO). Recent studies show YAP-TEAD signaling mediates the proliferative effects of WY-14643 during liver regeneration, clarifying its role in hepatomegaly (see Evidence & Benchmarks).

Biological Rationale

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated nuclear receptors that regulate lipid metabolism, inflammation, and cellular proliferation. PPARα activation induces fatty acid oxidation, reduces triglyceride levels, and modulates inflammatory signaling. WY-14643, a synthetic agonist, selectively targets PPARα, providing experimental control over these pathways. The compound is used to model metabolic disorders, dissect PPAR signaling, and study regeneration and inflammation in hepatic and vascular contexts (Sulfonhsssbiotin.com). This article updates and extends previous reviews by focusing on atomic, experimentally-verified claims, and integrating recent mechanistic advances such as YAP-TEAD mediation.

Mechanism of Action of WY-14643 (Pirinixic Acid)

WY-14643 (Pirinixic Acid) binds to the ligand-binding domain of PPARα, inducing a conformational change that promotes heterodimerization with retinoid X receptor (RXR). The activated complex binds to peroxisome proliferator response elements (PPREs) in DNA, upregulating genes involved in fatty acid transport, β-oxidation, and lipid clearance (Methylpseudo-utp.com). Aliphatic α-substitution further enhances agonist activity on both PPARα and PPARγ, creating dual-acting modulators suitable for comparative studies. In endothelial cells, WY-14643 suppresses TNF-α-stimulated VCAM-1 expression and monocyte adhesion, highlighting anti-inflammatory potential. In hepatic tissue, it indirectly raises TNFα mRNA via Kupffer cells, promoting hepatocyte mitogenesis. The YAP-TEAD pathway has been identified as a downstream effector in PPARα-induced hepatomegaly, as shown in recent mouse studies (see Evidence & Benchmarks).

Evidence & Benchmarks

• WY-14643 displays an IC₅₀ of 10.11 μM against human PPARα, confirming high selectivity (APExBIO).
• Aliphatic α-substitution increases dual PPARα/γ agonism, achieving activity in the lower micromolar range (Methylpseudo-utp.com).
• In endothelial cells, 250 μM WY-14643 reduces TNF-α-induced VCAM-1 expression and monocyte adhesion, indicating anti-inflammatory effects (PubMed).
• In high fat-fed rats, 3 mg/kg/day oral WY-14643 for two weeks lowers plasma glucose, triglycerides, leptin, and muscle triglycerides, while enhancing insulin sensitivity without increasing body weight (APExBIO).
• In mouse liver regeneration models, 100 mg/kg/day WY-14643 (i.p.) triggers hepatomegaly and YAP-TEAD-mediated proliferation; effects are abrogated in PPARα- or YAP-deficient mice (see Supporting Material).
• WY-14643 is insoluble in water but soluble in DMSO (≥16.2 mg/mL) and ethanol (≥48.8 mg/mL with ultrasonic assistance); storage at -20°C is required (APExBIO).

This article extends previous coverage by integrating recent YAP-TEAD mechanistic findings, and clarifies the distinction between direct anti-inflammatory and indirect mitogenic effects compared to earlier tumor microenvironment analyses.

Applications, Limits & Misconceptions

Validated Applications

• Metabolic disorder modeling: Induction of PPARα signaling for studies of lipid metabolism, fatty acid oxidation, and insulin sensitivity.
• Inflammation research: Suppression of TNF-α-driven VCAM-1 and monocyte adhesion in vascular assays.
• Hepatic regeneration: Investigation of PPARα-YAP-TEAD axis in liver proliferation and repair models.
• Dual PPARα/γ modulation: Comparative studies of isoform-selective versus dual-acting ligands.

Common Pitfalls or Misconceptions

• WY-14643 is not soluble in aqueous buffers without organic solvents; inappropriate vehicle selection causes precipitation and dose inconsistency.
• It is not a pan-PPAR agonist; PPARδ activity is negligible at physiologic concentrations.
• Observed mitogenic effects in the liver require intact YAP-TEAD signaling; results may not generalize to non-hepatic tissues.
• WY-14643 is for research use only and is not approved for diagnostic or therapeutic applications.
• Storage above -20°C or repeated freeze-thaw cycles degrade compound potency.

Workflow Integration & Parameters

WY-14643 (Pirinixic Acid) is supplied as a solid by APExBIO (SKU: A4305) and should be dissolved in DMSO or ethanol, achieving ≥16.2 mg/mL and ≥48.8 mg/mL solubility, respectively. Prepare working solutions fresh and store aliquots at -20°C for short-term use to maintain stability (product page). Standard experimental dosing includes 3 mg/kg/day orally in rats for metabolic studies, or 100 mg/kg/day i.p. in mice for hepatic regeneration protocols. For in vitro anti-inflammatory assays, 250 μM is effective for suppressing TNF-α-induced VCAM-1 expression. Always include appropriate vehicle controls and validate PPARα and YAP-TEAD pathway integrity for mechanistic studies. Extending prior protocol guides (Sulfonhsssbiotin.com), this article emphasizes precise vehicle selection and pathway verification as critical success factors.

Conclusion & Outlook

WY-14643 (Pirinixic Acid) remains a benchmark tool for dissecting PPARα signaling, modeling metabolic and inflammatory disease, and probing regeneration pathways in preclinical research. Its selectivity, dual agonist potential, and well-characterized pharmacodynamics enable reproducible, translationally relevant findings. Recent advances in understanding YAP-TEAD mediation expand its utility in regenerative biology. As always, strict adherence to validated protocols and awareness of compound limitations are essential for robust experimental outcomes.